Tag Archive for Direct Selling Public Companies

USANA Reports Q4 and Full Year 2025 Results

USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook.
Salt Lake City, Utah – USANA Health Sciences, Inc. (NYSE: USNA), a global leader in direct selling, today announced financial results for its fiscal fourth quarter and fiscal year ended January 3, 2026.

“USANA delivered fourth quarter net sales in line with our preliminary results announced on January 12, 2026,”

said Kevin Guest, Chairman and Chief Executive Officer.

“We began to see signs of stabilization in active customer counts in our core nutritional business as net sales in this segment increased modestly sequentially, led by growth in key markets including mainland China, the United States and Canada. Meanwhile, our omnichannel brands, Hiya and Rise, posted solid year-over-year growth.”

Key Financial and Operating Results

Q4 2025

Q4 2024

FY 2025

FY 2024

Net sales

$226.2

$213.6

$925.3

$854.5

Net (loss) earnings*

$-1.8

$4.5

$10.8

$42.0

Diluted EPS

$-0.10

$0.23

$0.58

$2.19

Adjusted diluted EPS(1)

$0.60

$0.64

$1.93

$2.59

Adjusted EBITDA(2)

$27.3

$25.5

$101.3

$110.3

USANA Active Customers

387,000

454,000

387,000

454,000

Hiya Active Monthly Subscribers

181,700

N/A

181,700

N/A

*Pretax earnings for Q4 2025 totaled $4.0 million with income tax expense of $5.8 million. The adjustment to income taxes during the period, largely as a result of one-time impairment and cost realignment charges, is about $3.1 million greater than what would have been expected using the previously expected 65% tax rate.

Net sales, Net (loss) earnings and Adjusted EBITDA figures

Read more...

USANA Reports Third Quarter 2025 Results

USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended September 27, 2025.
Key Financial Results
Third Quarter 2025 vs. Third Quarter 2024

Net sales of $214 million versus $200 million, representing 7% year-over-year growth.
Net loss of -$6.5 million versus net earnings of $10.6 million.
Diluted EPS of -$0.36 as compared with $0.56.
Adjusted diluted EPS(1) of -$0.15 as compared with $0.56.
Adjusted EBITDA(2) of $13.8 million versus $24.6 million.
Direct selling Active Customers of 388,000 versus 452,000.
Hiya Active Monthly Subscribers of 193,400.

Q3 2025 Financial Performance

Consolidated Results

Year-Over-Year

Sequentially

Net Sales

$214 million

+7% (No meaningful FX impact)

-9%

Net (Loss) Earnings*

-$6.5 million

N/A

N/A

Diluted EPS

-$0.36

N/A

N/A

Adjusted Diluted EPS(1)

-$0.15

N/A

N/A

Adjusted EBITDA(2)

$13.8 million

-44%

-55%

*Pretax earnings for Q3 2025 totaled $1.8 million with income tax expense of $8.5 million. The adjustment to income taxes during the period, as a result of updating the annual effective tax rate, is about $7.6 million greater than what would have been expected using the previously guided 45% tax rate.

Net earnings, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of 21.15% in Hiya.

“USANA provided third quarter results in line with the preliminary results we announced on October 9, 2025,”

said Jim Brown, USANA’s President and Chief Executive Officer.

“We rolled out our enhanced Brand Partner compensation plan

Read more...

Nu Skin Reports First Quarter Revenue at High End of Guidance

Nu Skin (NYSE: NUS) announced first quarter revenue at the high end of its guidance range.
Executive Summary: Q1 2025 vs. Prior-year Quarter

Revenue

$364.5 million; (12.7)%
(3.0)% FX impact or $(12.3) million

Earnings Per Share
(EPS)

$2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges

Customers

776,712; (11)%

Paid Affiliates

131,518; (15)%

Sales Leaders

31,036; (20)%

“We are pleased to achieve revenue at the high end of our guidance range and exceed our adjusted earnings forecast to start out the year,”

Ryan Napierski, Nu Skin president and CEO said.

“We drove year-over-year growth in Latin America and our Rhyz manufacturing segment, but we continue to experience consumer caution in premium beauty due to concerns such as inflation and tariffs in many parts of the world. Through 2025, we remain focused on building on our recent product launches and preparing for the preview of our Prysm iO intelligent wellness device in the back half of the year. This palm-sized device provides real-time insights into a customer’s health, informing recommendations for product subscriptions and increasing customer satisfaction and loyalty. We are also laying the groundwork for expansion into India with a market pre-opening in Q4 and formal launch in mid-2026 and prioritizing our efforts to continue improving margins across the board.”

Q1

Read more...